Clay Siegall: A Man On A Mission in The Fight Against Cancer
Cancer research has produced some amazing results in the fight against cancer. Some of the most promising drugs have been introduced in only the past two decades. The industry is buzzing with new reports, and these reports have some amazing news. England’s Chief Medical Officer has reported that small defects in DNA can possibly lead to cancer and other illnesses. The human body has an estimated 20,000 genes and one of the best ways of testing for illness is via DNA testing. This highly influential professional thinks that DNA testing should be mandated through blood tests and biopsies because the testing is very promising.
On the other hand, bladder cancer is a hot topic, and it’s causing a stir. Out of the 348 patients that took a urine test, 80 percent of the individuals had faulty proteins or TERT. This research was conducted in France at the University of Lyon. These simple urine tests are very efficient and effective for predicting bladder cancer or the recurrence of bladder cancer. This type of urine testing is twice as effective as the standard cytology testing. Thanks to the involvement of advanced-technologies, scientists and doctors can use specific machines to present and to read the results. Bladder cancer falls under Seattle Genetics’ jurisdiction, and this company has some of the leading cancer-fighting drugs on the planet. The company is lead by Dr. Clay Siegall. This man has up to 30 years of experience in the game by working with companies such as Bristol-Myers Squibb, the National Cancer Institute and the National Institute of Health. Seattle Genetics specializes in developing and commercializing cancer-breakthrough therapies.
Siegall founded the company in 1998 when it was a small startup, but as of today, it’s powerhouse in cancer research with close to 1,000 employees. In just the past few years, Seattle Genetics’ stock has tripled and that speaks volumes.